// App-Quantinova.ai

Sa1108 : Cost-Effectiveness of Golimumab Versus Infliximab and Adalimumab for the Treatment of Moderate to Severe Ulcerative Colitis

Researchers

Presenter

  • Eric Druyts

Principal Investigators

  • Steve Kanters

  • Shawn Eapen

  • Edward Mills

Medical Centers

  • Stanford Prevention Research Center, Stanford University, Vancouver, BC, Canada

  • University of Ottawa, Ottawa, ON, Canada

  • Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

  • School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • Infliximab

  • golimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved